Table 2.
Univariate analysis of prognostic factors correlated with PFS.
| Characteristics | mPFS (months) | HR (95%CI) | P value |
|---|---|---|---|
| HHLA2 expression | |||
| Low | 3.9 | Reference | |
| High | 31.7 | 0.233 (0.110 to 0.494) | <0.001 |
| Age | |||
| <60 | 6.1 | Reference | |
| ≥60 | 4.3 | 1.111 (0.637 to 1.936) | 0.711 |
| Gender | |||
| Male | 5.3 | Reference | |
| Female | 6.1 | 0.900 (0.549 to 1.475) | 0.676 |
| ECOG PS | |||
| 0 | 6.3 | Reference | |
| 1-2 | 1.7 | 3.624 (1.750 to 7.505) | 0.001 |
| LDH | |||
| Normal | 5.9 | Reference | |
| Elevated | 3.2 | 1.135 (0.592 to 2.176) | 0.702 |
| Subtype | |||
| Cutaneous | 6.1 | Reference | |
| Acral | 8.8 | 0.857 (0.494 to 1.489) | 0.585 |
| Mucosal | 3.5 | 1.623 (0.829 to 3.180) | 0.158 |
| Tumor stage | |||
| Stage III | 10.3 | Reference | |
| Stage IV | 5.3 | 1.143 (0.415 to 3.149) | 0.796 |
| Liver metastasis | |||
| No | 8.8 | Reference | |
| Yes | 1.9 | 3.081 (1.645 to 5.772) | <0.001 |
| Brain metastasis | |||
| No | 5.9 | Reference | |
| Yes | 2.8 | 1.714 (0.814 to 3.608) | 0.156 |
| Line of systematic treatment | |||
| First | 6.1 | Reference | |
| Second | 3.6 | 1.046 (0.593 to 1.843) | 0.877 |
| Type of immunotherapy | |||
| Anti-PD-1/PD-L1/CTLA4 monotherapy | 3.4 | Reference | |
| Anti-PD-1/PD-L1+Anti-CTLA-4 therapy | 20.3 | 0.565 (0.230 to 1.385) | 0.212 |
| Anti-PD-1/PD-L1+ other therapies | 5.9 | 0.899 (0.532 to 1.519) | 0.691 |
*P values <0.05 in bold are statistically significant.
HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenases; PD-1, programmed cell death protein-1; PD-L1, programmed death 1 ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.